Oncimmune Holdings plc announced changes to its leadership team and its Board of Directors. The company announced that Martin Gouldstone will be joining Oncimmune as its new Chief Executive Officer on 1 August 2023. Martin has over 25 years of experience in the life science sector, including senior commercial roles at a major CRO and most recently as Global Senior Vice President at Owkin Inc. Martin's commercial experience and connections will be a valuable asset in driving the Company's future business development activities.

Martin will also join the Company's Board of Directors and regulatory disclosures in relation to his appointment as required under Schedule 2(g) of the AIM Rules for Companies can be found at the foot of this announcement. Finally, after more than nine years with Oncimmune, Andrew Unitt will be stepping down as an Independent Non-Executive Director of the Company and as Chair of the Audit Committee on 30 September 2023. Andrew joined Oncimmune as non-executive director in 2014 and has chaired the Audit Committee since Oncimmune's IPO in 2016.

The Company has begun a search for a new Independent Non-Executive Director and Chair of the Audit Committee.